Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis-Reference-Cited by-同舟云学术

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis

Published:2009-05-08 Issue:1 Volume:219 Page:16-24
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Marchiò Caterina,Lambros Maryou B,Gugliotta Patrizia,Di Cantogno Ludovica Verdun,Botta Cristina,Pasini Barbara,Tan David SP,Mackay Alan,Fenwick Kerry,Tamber Narinder,Bussolati Gianni,Ashworth Alan,Reis-Filho Jorge S,Sapino Anna

Funder

NIHR Biomedical Research Centre

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/path.2574/fullpdf

Reference25 articles.

1. Chromogenic and fluorescent in situ hybridization in breast cancer;Lambros;Hum Pathol,2007

2. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer;Wolff;J Clin Oncol,2007

3. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer;Dal Lago;Mol Cancer Ther,2006

4. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice;Ma;Clin Cancer Res,2005

5. Concordance between central and local laboratory HER2 testing from a community-based clinical study;Reddy;Clin Breast Cancer,2006

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype;Modern Pathology;2024-08

2. Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab;npj Breast Cancer;2024-02-19

3. Molecular testing in breast cancer;Diagnostic Molecular Pathology;2024

4. Clinicopathologic Features of Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ≥6.0) Breast Cancers;Archives of Pathology & Laboratory Medicine;2023-11-07

5. Complementary Tumor Diagnosis by Single Cell–Based Cytogenetics Using Multi‐marker Fluorescence In Situ Hybridization (mFISH);Current Protocols;2023-11